Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Psyence Biomedical’s Subsidiary Gets Approval for Phase IIb Psychedelic Study
Details : Psilocybin acts as an agonist at serotonin type 2A (5-HT2A) receptors, producing a "mystical-like" hallucinatory effect, being investigated for adjustment disorders treatment.
Product Name : PEX010
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 03, 2024
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : $0.7 million
Deal Type : Private Placement
PharmAla Closes Private Placement and Concurrent Debt Settlement
Details : Net proceeds will support development of novel intellectual property assets, including ALA-002 (3,4-methylenedioxymethamphetamine) for treating PTSD and social anxiety in autistic adults.
Product Name : ALA-002
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 19, 2024
Lead Product(s) : Midomafetamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : $0.7 million
Deal Type : Private Placement
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Revive Therapeutics Updates Psilocybin Clinical Study for Methamphetamine Use Disorder
Details : The Company’s clinical study is evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an investigator-initiated IND.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 04, 2024
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deuterated Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
Details : CYB004 (deuterated dimethyltryptamine) is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Product Name : CYB004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2023
Lead Product(s) : Deuterated Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agit...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deuterated Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
Details : CYB004 (deuterated dimethyltryptamine) is a psychedelic tryptamine, non-selective agonist for 5HT2a receptor being developed as a therapy for patients with neurological & mental illness.
Product Name : CYB004
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2023
Lead Product(s) : Deuterated Dimethyltryptamine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : FAV LS Fund I
Deal Size : Undisclosed
Deal Type : Financing
Details : Proceeds from the fund's investment will support Diamond's collaboration with UAB on an investigator-led clinical trial of low-dose psilocybin to treat demoralization.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 04, 2023
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : FAV LS Fund I
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
Details : Psilocybin reacts agonistically with 5-HT2A receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety effects. Being developed for methamphetamine ...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Psilocybin reacts agonistically with serotonin (5-hydroxytryptamine) type 2A (5-HT2A) receptors to produce a “mystical-like” hallucinatory effect due to induced frontal hyper-frontality, which in turn mediates its anti-depressant and anti-anxiety eff...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : Psilocybine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isoprocin Prodrug
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : MPM BioImpact
Deal Size : $13.1 million
Deal Type : Acquisition
Reunion Neuroscience Announces US$13.1 Million Take-Private Transaction with MPM BioImpact
Details : MPM BioImpact will develop next-generation solutions for underserved mental health conditions including, RE104, a proprietary, novel, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, being developed for postpartum...
Product Name : RE104
Product Type : Other Small Molecule
Upfront Cash : $13.1 million
January 06, 2023
Lead Product(s) : Isoprocin Prodrug
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : MPM BioImpact
Deal Size : $13.1 million
Deal Type : Acquisition